<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00523809</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0873</org_study_id>
    <nct_id>NCT00523809</nct_id>
  </id_info>
  <brief_title>Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor</brief_title>
  <official_title>Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if giving Avastin (bevacizumab) with
      standard chemotherapy and a blood stem cell transplant, in patients with an advanced solid
      tumor, can help to shrink the tumor or slow its growth. The safety of this treatment will
      also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:

      Bevacizumab is designed to prevent or slow down the growth of cancer cells by blocking the
      growth of blood vessels.

      The combination of standard chemotherapy drugs (fludarabine and melphalan) used for this
      study may help to improve the chances of your body accepting the stem cell transplant.
      Fludarabine is designed to make cancer cells less able to repair damaged DNA (the genetic
      material of cells) and weaken the immune system so that stem cells can stay in your body.
      Melphalan is designed to damage the cancer cells' DNA.

      Study Drug Administration:

      If you are found to be eligible to take part in this study, you will have a central venous
      catheter inserted. A central venous catheter is a sterile flexible tube that will be placed
      into a large vein while you are under local anesthesia. Your doctor will explain this
      procedure to you in more detail, and you will be required to sign a separate consent form for
      this procedure.

      You will receive chemotherapy with bevacizumab, fludarabine, and melphalan in order to
      prepare for the stem cell transplant.

      On Day 1, you will receive bevacizumab through a needle in your vein over 30 minutes.

      On Days 2-6, you will receive fludarabine by vein over 30 minutes.

      On Day 5-6, you will receive melphalan by vein over 30 minutes.

      On Day 7, you will receive no study drugs.

      Stem Cell Transplant and Post-Transplant Drug Administration:

      On Day 8, you will have a stem cell transplant. Your study doctor will explain this procedure
      to you in more detail and you will sign a separate consent form.

      After the transplant, you will receive the drugs tacrolimus and methotrexate. Tacrolimus and
      methotrexate are used to prevent graft versus host disease (GVHD), a condition that occurs
      when the transplanted cells attack the normal cells in the body.

      Tacrolimus will be given by vein non-stop (24 hours a day) until you are able to take
      medications by mouth. Once you are able to take medications by mouth, your doctor will tell
      you how and when to take the oral medication. You will receive tacrolimus for 2-3 months.
      During the last month that tacrolimus is given, the dose will be lowered gradually.

      Methotrexate will be given by vein over a few seconds on Days 9, 11, and 14. An additional
      dose of methotrexate will be given on Day 19 if your donor is your parent, child, or an
      unrelated family member.

      If GVHD does occur, the GVHD will be treated with methylprednisolone by vein or by mouth, as
      needed. You may also be given steroid cream to use on the skin, if needed.

      Starting at least 3 weeks after the transplant, as soon as your blood counts recover, you
      will receive bevacizumab every 2 weeks by vein over 30 minutes.

      Post-Transplant Procedures:

      You must stay in the hospital for about 3-4 weeks beginning on Day 1. While you are in the
      hospital, blood (about 2 teaspoons) will be drawn for routine tests every day.

      You must stay in the Houston area for about 100 days after the transplant. Once a month
      during the 100 days after the transplant, and then every 3 months for the first year, you
      will have scans to check the status of the disease. The study doctor will decide which scans
      are necessary (chest x-rays, CT scans, and/or bone scans). You may also have a bone marrow
      aspirate and biopsy at these times. The bone marrow aspirate and biopsy would only be
      performed if your bone marrow was shown to be involved with the disease at the time of
      screening.

      If the disease is still present at 2 months after the transplant, and you do not have GVHD,
      you will stop receiving tacrolimus within 2 weeks. After that, if the disease is still
      present after another 6 weeks, and you do not have GVHD, you may receive an infusion of donor
      lymphocytes (a type of white blood cell) by vein over about 30 minutes. This treatment with
      white blood cells may be repeated 2 more times with 6 weeks between each infusion.

      Length of Study:

      You will be taken off-study after 1 year.

      Follow-Up Visits:

      You will have follow-up visits as per standard of care.

      This is an investigational study. The use of bevacizumab in transplant patients is not FDA
      approved. Melphalan and fludarabine are FDA approved and commercially available for
      transplant patients. Up to 18 patients will take part in this study. All will be enrolled at
      M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual.
  </why_stopped>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>100 days after transplant</time_frame>
    <description>Number or participants with no disease progression or death for any reason during first 100 days following transplantation. Participants followed every 3 months for first year.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Bevacizumab + Fludarabine + Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab 10 mg/kg intravenous (IV) on Day 1; Fludarabine 25 mg/m^2 IV Daily over 5 Days; Melphalan 70 mg/m^2 IV Daily over 2 Days; Thymoglobulin 0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1; plus Allogeneic Hematopoietic Stem Cell Transplantation on Day 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>10 mg/kg IV Daily Over 30 Minutes for 1 Day</description>
    <arm_group_label>Bevacizumab + Fludarabine + Melphalan</arm_group_label>
    <other_name>Avastinâ„¢</other_name>
    <other_name>Anti-VEGF monoclonal antibody</other_name>
    <other_name>rhuMAb-VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Stem Cell Transplantation on Day 8.</description>
    <arm_group_label>Bevacizumab + Fludarabine + Melphalan</arm_group_label>
    <other_name>NST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25 mg/m^2 IV Daily Over 30 Minutes for 5 Days</description>
    <arm_group_label>Bevacizumab + Fludarabine + Melphalan</arm_group_label>
    <other_name>Fludarabine Phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>70 mg/m^2 IV Daily Over 30 Minutes for 2 Days</description>
    <arm_group_label>Bevacizumab + Fludarabine + Melphalan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1.</description>
    <arm_group_label>Bevacizumab + Fludarabine + Melphalan</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>Antithymocyte Globulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. From Age 18 to Age &lt;/= 65 years old.

          2. Patients must have one of the following diseases. 1) metastatic breast cancer which
             achieved a tumor response (complete response (CR) or partial response (PR)) by
             pre-transplant therapy. For bone only metastatic breast cancer, a tumor response of
             stable disease (SD) is accepted. 2) low grade advanced ovarian cancer 3) high grade
             advanced ovarian cancer which achieved antitumor response (CR or PR) by pre-transplant
             therapy.

          3. Zubrod performance status &lt;/= 1.

          4. An HLA-matched (6/6 matches) related donor or unrelated donor (8/8 matches) willing
             and able to donate peripheral blood stem cell (PBSC) or bone marrow and/or lymphocytes
             by conventional techniques.

          5. Requirement of prior treatment. For metastatic renal cell carcinoma (RCC) two prior
             treatments, which include targeted therapy (e.g. Sorafenib and Stutent). For breast
             and ovarian cancer, one prior treatment which include chemotherapy.

          6. Adequate major organ functions.

          7. Signed informed consent.

          8. Left ventricular ejection fraction &gt;/= 45%. Cardiology clearance is needed if the
             patient has left ventricular ejection fraction of &lt; 45%, uncontrolled arrhythmias, or
             symptomatic cardiac disease.

          9. Forced expiratory volume in 1 second (FEV1), Forced vital capacity (FVC), and carbon
             monoxide diffusing capacity (DLCO) &gt;/= 50% of predicted value. Pulmonary clearance is
             needed if the patient has FEV1, FVC, or DLCO &lt; 50% of predicted valued or any
             symptomatic pulmonary disease.

         10. Serum creatinine &lt;/= 2.0 mg/dL, or creatinine clearance &gt; 40 mL/min.

         11. Serum bilirubin &lt;/= 1.5 mg/dL, and serum glutamic-pyruvic transaminase (SGPT) &lt;/= 3 *
             upper limit of normal.

        Exclusion Criteria:

          1. Prior history of allogeneic stem cell transplantation.

          2. Life expectancy is severely limited by concomitant illness.

          3. Clinically significant active infections.

          4. HIV infection.

          5. Chronic active hepatitis.

          6. Pregnant or lactating women.

          7. Presence of, or prior history of multiple brain metastasis. If patient has prior
             single brain metastasis treated with complete surgical resection or stereotactic
             radiation therapy, radiological imaging has to demonstrate no recurrence or no brain
             edema for at least 6 months from the end of the treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naoto Ueno, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2007</study_first_submitted>
  <study_first_submitted_qc>August 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2007</study_first_posted>
  <results_first_submitted>December 21, 2012</results_first_submitted>
  <results_first_submitted_qc>December 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 28, 2013</results_first_posted>
  <last_update_submitted>December 21, 2012</last_update_submitted>
  <last_update_submitted_qc>December 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Avastin</keyword>
  <keyword>Thymoglobulin</keyword>
  <keyword>ATG</keyword>
  <keyword>Antithymocyte Globulin</keyword>
  <keyword>Allogeneic Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>AHSCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: August 30. 2007 through November 2, 2010. All recruitment was done at UT MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab + Fludarabine + Melphalan</title>
          <description>Bevacizumab 10 mg/kg intravenous (IV) on Day 1; Fludarabine 25 mg/m^2 IV Daily over 5 Days; Melphalan 70 mg/m^2 IV Daily over 2 Days; Thymoglobulin 0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1; plus Allogeneic Hematopoietic Stem Cell Transplantation on Day 8.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab + Fludarabine + Melphalan</title>
          <description>Bevacizumab 10 mg/kg intravenous (IV) on Day 1; Fludarabine 25 mg/m^2 IV Daily over 5 Days; Melphalan 70 mg/m^2 IV Daily over 2 Days; Thymoglobulin 0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1; plus Allogeneic Hematopoietic Stem Cell Transplantation on Day 8.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="45" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Number or participants with no disease progression or death for any reason during first 100 days following transplantation. Participants followed every 3 months for first year.</description>
        <time_frame>100 days after transplant</time_frame>
        <population>Study objectives were not meet, analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Fludarabine + Melphalan</title>
            <description>Bevacizumab 10 mg/kg intravenous (IV) on Day 1; Fludarabine 25 mg/m^2 IV Daily over 5 Days; Melphalan 70 mg/m^2 IV Daily over 2 Days; Thymoglobulin 0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1; plus Allogeneic Hematopoietic Stem Cell Transplantation on Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Number or participants with no disease progression or death for any reason during first 100 days following transplantation. Participants followed every 3 months for first year.</description>
          <population>Study objectives were not meet, analysis was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year and 7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab + Fludarabine + Melphalan</title>
          <description>Bevacizumab 10 mg/kg intravenous (IV) on Day 1; Fludarabine 25 mg/m^2 IV Daily over 5 Days; Melphalan 70 mg/m^2 IV Daily over 2 Days; Thymoglobulin 0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1; plus Allogeneic Hematopoietic Stem Cell Transplantation on Day 8.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac toxicity, reduced ejection fraction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mild depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal bleed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hot flash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vaginal itch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Mild breast pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Face swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Naoto Ueno, MD / Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

